Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) gapped down prior to trading on Tuesday . The stock had previously closed at $36.45, but opened at $35.54. Xenon Pharmaceuticals shares last traded at $35.66, with a volume of 16,629 shares traded.
Analyst Upgrades and Downgrades
Several research analysts have weighed in on XENE shares. HC Wainwright reiterated a "buy" rating and issued a $53.00 price target on shares of Xenon Pharmaceuticals in a report on Monday, February 24th. Deutsche Bank Aktiengesellschaft started coverage on Xenon Pharmaceuticals in a research note on Tuesday, February 11th. They issued a "buy" rating and a $67.00 target price for the company. Royal Bank of Canada reissued an "outperform" rating on shares of Xenon Pharmaceuticals in a research note on Friday, February 28th. William Blair reaffirmed an "outperform" rating on shares of Xenon Pharmaceuticals in a research note on Friday, February 28th. Finally, StockNews.com upgraded shares of Xenon Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $57.38.
Check Out Our Latest Research Report on XENE
Xenon Pharmaceuticals Stock Performance
The stock has a fifty day moving average price of $37.72 and a 200-day moving average price of $39.73. The firm has a market cap of $2.62 billion, a PE ratio of -12.15 and a beta of 1.26.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.05. As a group, equities analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current fiscal year.
Insider Buying and Selling
In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 22,468 shares of the firm's stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $40.20, for a total value of $903,213.60. Following the transaction, the chief executive officer now directly owns 31,302 shares of the company's stock, valued at $1,258,340.40. This trade represents a 41.79 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 5.52% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Xenon Pharmaceuticals
A number of large investors have recently modified their holdings of XENE. Occudo Quantitative Strategies LP boosted its holdings in Xenon Pharmaceuticals by 5.8% in the 4th quarter. Occudo Quantitative Strategies LP now owns 11,441 shares of the biopharmaceutical company's stock worth $448,000 after acquiring an additional 630 shares during the period. Geode Capital Management LLC lifted its position in shares of Xenon Pharmaceuticals by 1.0% during the fourth quarter. Geode Capital Management LLC now owns 69,529 shares of the biopharmaceutical company's stock worth $2,726,000 after purchasing an additional 720 shares in the last quarter. KBC Group NV boosted its stake in shares of Xenon Pharmaceuticals by 39.8% in the fourth quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company's stock valued at $107,000 after purchasing an additional 780 shares during the period. HighVista Strategies LLC boosted its stake in shares of Xenon Pharmaceuticals by 1.4% in the third quarter. HighVista Strategies LLC now owns 73,762 shares of the biopharmaceutical company's stock valued at $2,904,000 after purchasing an additional 1,047 shares during the period. Finally, HighMark Wealth Management LLC increased its stake in Xenon Pharmaceuticals by 22.0% during the 4th quarter. HighMark Wealth Management LLC now owns 6,100 shares of the biopharmaceutical company's stock worth $239,000 after buying an additional 1,100 shares during the period. Institutional investors and hedge funds own 95.45% of the company's stock.
Xenon Pharmaceuticals Company Profile
(
Get Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Recommended Stories
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
